On August 10, WUXI XDC rose 3.39% in regular trading, trading at HKD 63.4/share, with turnover of HKD 65.74 million.
On the news front, the company is scheduled to hold a board meeting on August 24 to review its interim results for the first half of the year, fueling market expectations for robust growth at the global ADC outsourcing leader. CLSA recently raised its target price to HKD 82.6, maintaining an Outperform rating, forecasting revenue and adjusted net profit growth exceeding guidance. Daiwa initiated coverage with a Buy rating and HKD 78 target price, naming it a top pick in the China CXO sector.
Sector linkage effects remained evident, with WUXI APPTEC up 4.11%, WUXI BIO up 2.92%, INSILICO up 5.28%, and XTALPI up 6.23%. The recovery in global biotech financing and strong ADC R&D investment continue to drive early positioning by institutional capital.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)